# A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06312982/  
OnCo record `nct06312982` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of tislelizumab in colorectal cancer, run by Beijing Friendship Hospital, now recruiting.

## Summary

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT06312982 by Beijing Friendship Hospital, with a registry enrolment figure of 375 participants, started 2024-03-16 and due to reach its primary completion in 2026-12-01. Interventions recorded: Tislelizumab. Conditions listed: Locally Advanced Rectal Carcinoma. Primary outcome: CR. Colorectal eligibility wording from the registry: "Pathohistologically confirmed rectal adenocarcinoma, along with immunohistochemical results of pMMR or genetic test results of MSS;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06312982
- Phase: 2/3
- Setting: A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
- Sponsor: Beijing Friendship Hospital
- Enrolled: 375

## Sources

- ClinicalTrials.gov NCT06312982: https://clinicaltrials.gov/study/NCT06312982

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06312982.json